Embolization Particle Market By Type (Radioembolization Particle, Microspheres Particles, Drug Eluting Beads, PVA Particles, Gelfoam Particles, Others) , By Application (Oncology, Peripheral Vascular Disease, Neurovascular Disease, Urology, Others) By En
Description
Embolization Particle Market By Type (Radioembolization Particle, Microspheres Particles, Drug Eluting Beads, PVA Particles, Gelfoam Particles, Others) , By Application (Oncology, Peripheral Vascular Disease, Neurovascular Disease, Urology, Others) By End User (Hospitals, Ambulatory Surgical Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Embolization Particle Market
The embolization particle market was valued at $1.3 billion in 2023 and is projected to reach $3.6 billion by 2033, growing at a CAGR of 10.7% from 2024 to 2033.
An embolization particle is a specialized device designed to perform minimally invasive procedure of obstructing blood vessels. The device finds applications in the treatment of different conditions such as tumors, variceal bleeding, uterine fibroid embolization, and vascular malformations. The major benefits of using embolization particles are that they facilitate targeted treatment and offer customization options regarding the size of particle according to the treatment goals.
Increase in the prevalence of vascular disorders such as arteriovenous malformations and tumors is a key driver of the embolization particle market. In addition, rise in the popularity of minimally invasive procedures propels the growth of the market. Furthermore, advancements in the equipment such as integration of drug-eluting beads augments the development of the market. The use of advanced technologies such as additive manufacturing and nanotechnology for the development of embolization particles is a notable trend gaining prominence in the market. These technologies enhance the precision of the device and assist in delivering tailored treatment to patients based on their profiles & desired outcomes.
However, high cost of embolization particles deters budget-sensitive healthcare facilities from investing in them, restraining the development of the market. Furthermore, handling of the device requires practitioners with significant skills and experience, lack of which hampers the market development. On the contrary, rise in inclination toward sustainability is anticipated to present lucrative opportunities for the embolization particle market growth. Manufacturers are focusing on the generation of biodegradable agents for integration into embolization particles and reduce the impact over environment. Biodegradable agents are efficiently assisting in conditions where temporary embolization is required. The key attributes of a biodegradable agent include fate of degraded fragment, occlusion period, and therapeutic loading capability.
Segment Review
The embolization particle market is segmented into type, application, end user, and region. On the basis of type, the market is divided into radioembolization particle, microspheres particles, drug eluting beads, PVA particles, gelfoam particles, and others. Depending on application, it is classified into oncology, peripheral vascular disease, neurovascular disease, urology, and others. By end user, it is categorized into hospitals, ambulatory surgical centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of type, the radioembolization particle segment dominates the market.
Depending on application, the oncology segment accounts for a high share of the market.
By end user, the hospitals segment acquires a high stake in the market.
Region wise, North America is projected to be the highest revenue generator by 2033.
Competition Analysis
The major players of the global embolization particle market include Boston Scientific Corporation, Medtronic Plc, Merit Medical Systems, Inc., Terumo Corporation, Cook Medical, Stryker Corporation, Penumbra, Inc., Sirtex Medical Limited, Johnson & Johnson, and Kaneka Corporation. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Key Market Segments
By Type
Radioembolization Particle
Microspheres Particles
Drug Eluting Beads
PVA Particles
Gelfoam Particles
Others
By Application
Oncology
Peripheral Vascular Disease
Neurovascular Disease
Urology
Others
By End User
Hospitals
Ambulatory Surgical Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Boston Scientific Corporation
Medtronic plc
Merit Medical Systems, Inc.
Terumo Corporation
Cook Medical
Stryker Corporation.
Penumbra, Inc.
Sirtex Medical Limited
Johnson & Johnson
Kaneka Corporation.
Table of Contents
260 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: EMBOLIZATION PARTICLE MARKET, BY TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
- 4.2. Radioembolization Particle
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Microspheres Particles
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Drug Eluting Beads
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- 4.5. PVA Particles
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
- 4.6. Gelfoam Particles
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
- 4.7. Others
- 4.7.1. Key Market Trends, Growth Factors and Opportunities
- 4.7.2. Market Size and Forecast, By Region
- 4.7.3. Market Share Analysis, By Country
- CHAPTER 5: EMBOLIZATION PARTICLE MARKET, BY APPLICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
- 5.2. Oncology
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Peripheral Vascular Disease
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Neurovascular Disease
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- 5.5. Urology
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country
- 5.6. Others
- 5.6.1. Key Market Trends, Growth Factors and Opportunities
- 5.6.2. Market Size and Forecast, By Region
- 5.6.3. Market Share Analysis, By Country
- CHAPTER 6: EMBOLIZATION PARTICLE MARKET, BY END USER
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
- 6.2. Hospitals
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Ambulatory Surgical Centers
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Others
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: EMBOLIZATION PARTICLE MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Embolization Particle Market
- 7.2.6.1. Market Size and Forecast, By Type
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Embolization Particle Market
- 7.2.7.1. Market Size and Forecast, By Type
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Embolization Particle Market
- 7.2.8.1. Market Size and Forecast, By Type
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By End User
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Embolization Particle Market
- 7.3.6.1. Market Size and Forecast, By Type
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. Germany Embolization Particle Market
- 7.3.7.1. Market Size and Forecast, By Type
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. Italy Embolization Particle Market
- 7.3.8.1. Market Size and Forecast, By Type
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Spain Embolization Particle Market
- 7.3.9.1. Market Size and Forecast, By Type
- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. UK Embolization Particle Market
- 7.3.10.1. Market Size and Forecast, By Type
- 7.3.10.2. Market Size and Forecast, By Application
- 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest Of Europe Embolization Particle Market
- 7.3.11.1. Market Size and Forecast, By Type
- 7.3.11.2. Market Size and Forecast, By Application
- 7.3.11.3. Market Size and Forecast, By End User
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Embolization Particle Market
- 7.4.6.1. Market Size and Forecast, By Type
- 7.4.6.2. Market Size and Forecast, By Application
- 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. Japan Embolization Particle Market
- 7.4.7.1. Market Size and Forecast, By Type
- 7.4.7.2. Market Size and Forecast, By Application
- 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. India Embolization Particle Market
- 7.4.8.1. Market Size and Forecast, By Type
- 7.4.8.2. Market Size and Forecast, By Application
- 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. South Korea Embolization Particle Market
- 7.4.9.1. Market Size and Forecast, By Type
- 7.4.9.2. Market Size and Forecast, By Application
- 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. Australia Embolization Particle Market
- 7.4.10.1. Market Size and Forecast, By Type
- 7.4.10.2. Market Size and Forecast, By Application
- 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Embolization Particle Market
- 7.4.11.1. Market Size and Forecast, By Type
- 7.4.11.2. Market Size and Forecast, By Application
- 7.4.11.3. Market Size and Forecast, By End User
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Embolization Particle Market
- 7.5.6.1. Market Size and Forecast, By Type
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. South Africa Embolization Particle Market
- 7.5.7.1. Market Size and Forecast, By Type
- 7.5.7.2. Market Size and Forecast, By Application
- 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. Saudi Arabia Embolization Particle Market
- 7.5.8.1. Market Size and Forecast, By Type
- 7.5.8.2. Market Size and Forecast, By Application
- 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Embolization Particle Market
- 7.5.9.1. Market Size and Forecast, By Type
- 7.5.9.2. Market Size and Forecast, By Application
- 7.5.9.3. Market Size and Forecast, By End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Boston Scientific Corporation
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Medtronic Plc
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Merit Medical Systems, Inc.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Terumo Corporation
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Cook Medical
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Stryker Corporation.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Penumbra, Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Sirtex Medical Limited
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Johnson And Johnson
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Kaneka Corporation.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 2. EMBOLIZATION PARTICLE MARKET FOR RADIOEMBOLIZATION PARTICLE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. EMBOLIZATION PARTICLE MARKET FOR MICROSPHERES PARTICLES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. EMBOLIZATION PARTICLE MARKET FOR DRUG ELUTING BEADS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. EMBOLIZATION PARTICLE MARKET FOR PVA PARTICLES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 6. EMBOLIZATION PARTICLE MARKET FOR GELFOAM PARTICLES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. EMBOLIZATION PARTICLE MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. GLOBAL EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 9. EMBOLIZATION PARTICLE MARKET FOR ONCOLOGY, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. EMBOLIZATION PARTICLE MARKET FOR PERIPHERAL VASCULAR DISEASE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. EMBOLIZATION PARTICLE MARKET FOR NEUROVASCULAR DISEASE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. EMBOLIZATION PARTICLE MARKET FOR UROLOGY, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. EMBOLIZATION PARTICLE MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 14. GLOBAL EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 15. EMBOLIZATION PARTICLE MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 16. EMBOLIZATION PARTICLE MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 17. EMBOLIZATION PARTICLE MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 18. EMBOLIZATION PARTICLE MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 19. NORTH AMERICA EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 20. NORTH AMERICA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 21. NORTH AMERICA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 22. NORTH AMERICA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 23. U.S. EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 24. U.S. EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 25. U.S. EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 26. CANADA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 27. CANADA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 28. CANADA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 29. MEXICO EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 30. MEXICO EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 31. MEXICO EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 32. EUROPE EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 33. EUROPE EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 34. EUROPE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 35. EUROPE EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 36. FRANCE EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 37. FRANCE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 38. FRANCE EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 39. GERMANY EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 40. GERMANY EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 41. GERMANY EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 42. ITALY EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 43. ITALY EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 44. ITALY EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 45. SPAIN EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 46. SPAIN EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 47. SPAIN EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 48. UK EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 49. UK EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 50. UK EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 51. REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 52. REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 53. REST OF EUROPE EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 54. ASIA-PACIFIC EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 55. ASIA-PACIFIC EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 56. ASIA-PACIFIC EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 57. ASIA-PACIFIC EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 58. CHINA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 59. CHINA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 60. CHINA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 61. JAPAN EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 62. JAPAN EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 63. JAPAN EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 64. INDIA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 65. INDIA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 66. INDIA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 67. SOUTH KOREA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 68. SOUTH KOREA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 69. SOUTH KOREA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 70. AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 71. AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 72. AUSTRALIA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 73. REST OF ASIA-PACIFIC EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 74. REST OF ASIA-PACIFIC EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 75. REST OF ASIA-PACIFIC EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 76. LAMEA EMBOLIZATION PARTICLE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 77. LAMEA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 78. LAMEA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 79. LAMEA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 80. BRAZIL EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 81. BRAZIL EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 82. BRAZIL EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 83. SOUTH AFRICA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 84. SOUTH AFRICA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 85. SOUTH AFRICA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 86. SAUDI ARABIA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 87. SAUDI ARABIA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 88. SAUDI ARABIA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 89. REST OF LAMEA EMBOLIZATION PARTICLE MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 90. REST OF LAMEA EMBOLIZATION PARTICLE MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 91. REST OF LAMEA EMBOLIZATION PARTICLE MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 92. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
- TABLE 93. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
- TABLE 94. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
- TABLE 95. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
- TABLE 96. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 97. MEDTRONIC PLC: KEY EXECUTIVES
- TABLE 98. MEDTRONIC PLC: COMPANY SNAPSHOT
- TABLE 99. MEDTRONIC PLC: OPERATING SEGMENTS
- TABLE 100. MEDTRONIC PLC: PRODUCT PORTFOLIO
- TABLE 101. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 102. MERIT MEDICAL SYSTEMS, INC.: KEY EXECUTIVES
- TABLE 103. MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT
- TABLE 104. MERIT MEDICAL SYSTEMS, INC.: OPERATING SEGMENTS
- TABLE 105. MERIT MEDICAL SYSTEMS, INC.: PRODUCT PORTFOLIO
- TABLE 106. MERIT MEDICAL SYSTEMS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 107. TERUMO CORPORATION: KEY EXECUTIVES
- TABLE 108. TERUMO CORPORATION: COMPANY SNAPSHOT
- TABLE 109. TERUMO CORPORATION: OPERATING SEGMENTS
- TABLE 110. TERUMO CORPORATION: PRODUCT PORTFOLIO
- TABLE 111. TERUMO CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 112. COOK MEDICAL: KEY EXECUTIVES
- TABLE 113. COOK MEDICAL: COMPANY SNAPSHOT
- TABLE 114. COOK MEDICAL: OPERATING SEGMENTS
- TABLE 115. COOK MEDICAL: PRODUCT PORTFOLIO
- TABLE 116. COOK MEDICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 117. STRYKER CORPORATION.: KEY EXECUTIVES
- TABLE 118. STRYKER CORPORATION.: COMPANY SNAPSHOT
- TABLE 119. STRYKER CORPORATION.: OPERATING SEGMENTS
- TABLE 120. STRYKER CORPORATION.: PRODUCT PORTFOLIO
- TABLE 121. STRYKER CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 122. PENUMBRA, INC.: KEY EXECUTIVES
- TABLE 123. PENUMBRA, INC.: COMPANY SNAPSHOT
- TABLE 124. PENUMBRA, INC.: OPERATING SEGMENTS
- TABLE 125. PENUMBRA, INC.: PRODUCT PORTFOLIO
- TABLE 126. PENUMBRA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 127. SIRTEX MEDICAL LIMITED: KEY EXECUTIVES
- TABLE 128. SIRTEX MEDICAL LIMITED: COMPANY SNAPSHOT
- TABLE 129. SIRTEX MEDICAL LIMITED: OPERATING SEGMENTS
- TABLE 130. SIRTEX MEDICAL LIMITED: PRODUCT PORTFOLIO
- TABLE 131. SIRTEX MEDICAL LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 132. JOHNSON AND JOHNSON: KEY EXECUTIVES
- TABLE 133. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 134. JOHNSON AND JOHNSON: OPERATING SEGMENTS
- TABLE 135. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 136. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 137. KANEKA CORPORATION.: KEY EXECUTIVES
- TABLE 138. KANEKA CORPORATION.: COMPANY SNAPSHOT
- TABLE 139. KANEKA CORPORATION.: OPERATING SEGMENTS
- TABLE 140. KANEKA CORPORATION.: PRODUCT PORTFOLIO
- TABLE 141. KANEKA CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL EMBOLIZATION PARTICLE MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF EMBOLIZATION PARTICLE MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN EMBOLIZATION PARTICLE MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALEMBOLIZATION PARTICLE MARKET
- FIGURE 10. GLOBAL EMBOLIZATION PARTICLE MARKET SEGMENTATION, BY TYPE
- FIGURE 11. EMBOLIZATION PARTICLE MARKET FOR RADIOEMBOLIZATION PARTICLE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. EMBOLIZATION PARTICLE MARKET FOR MICROSPHERES PARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. EMBOLIZATION PARTICLE MARKET FOR DRUG ELUTING BEADS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. EMBOLIZATION PARTICLE MARKET FOR PVA PARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. EMBOLIZATION PARTICLE MARKET FOR GELFOAM PARTICLES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. EMBOLIZATION PARTICLE MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. GLOBAL EMBOLIZATION PARTICLE MARKET SEGMENTATION, BY APPLICATION
- FIGURE 18. EMBOLIZATION PARTICLE MARKET FOR ONCOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. EMBOLIZATION PARTICLE MARKET FOR PERIPHERAL VASCULAR DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. EMBOLIZATION PARTICLE MARKET FOR NEUROVASCULAR DISEASE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. EMBOLIZATION PARTICLE MARKET FOR UROLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 22. EMBOLIZATION PARTICLE MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 23. GLOBAL EMBOLIZATION PARTICLE MARKET SEGMENTATION, BY END USER
- FIGURE 24. EMBOLIZATION PARTICLE MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 25. EMBOLIZATION PARTICLE MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 26. EMBOLIZATION PARTICLE MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 31. COMPETITIVE DASHBOARD
- FIGURE 32. COMPETITIVE HEATMAP: EMBOLIZATION PARTICLE MARKET
- FIGURE 33. TOP PLAYER POSITIONING, 2023
- FIGURE 34. BOSTON SCIENTIFIC CORPORATION: NET SALES, 2021-2023 ($BILLION)
- FIGURE 35. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 36. BOSTON SCIENTIFIC CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 37. MEDTRONIC PLC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 38. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 39. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 40. MERIT MEDICAL SYSTEMS, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 41. MERIT MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 42. MERIT MEDICAL SYSTEMS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 43. TERUMO CORPORATION: NET SALES, 2021-2023 ($BILLION)
- FIGURE 44. TERUMO CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 45. TERUMO CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 46. COOK MEDICAL: NET SALES, 2021-2023 ($BILLION)
- FIGURE 47. COOK MEDICAL: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 48. COOK MEDICAL: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 49. STRYKER CORPORATION.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 50. STRYKER CORPORATION.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 51. STRYKER CORPORATION.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 52. PENUMBRA, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 53. PENUMBRA, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 54. PENUMBRA, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 55. SIRTEX MEDICAL LIMITED: NET SALES, 2021-2023 ($BILLION)
- FIGURE 56. SIRTEX MEDICAL LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 57. SIRTEX MEDICAL LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 58. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
- FIGURE 59. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 60. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 61. KANEKA CORPORATION.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 62. KANEKA CORPORATION.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 63. KANEKA CORPORATION.: REVENUE SHARE, BY REGION, 2023 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
